These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 27698247)

  • 41. EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis.
    Pickard AS; Gooderham M; Hartz S; Nicolay C
    J Med Econ; 2017 Jan; 20(1):19-27. PubMed ID: 27471948
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The impact of age on health utility values for older women with early-stage breast cancer: a systematic review and meta-regression.
    Wang Y; Gavan SP; Steinke D; Cheung KL; Chen LC
    Health Qual Life Outcomes; 2022 Dec; 20(1):169. PubMed ID: 36564800
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The economic impact of multiple sclerosis in Australia in 2010.
    Palmer AJ; Colman S; O'Leary B; Taylor BV; Simmons RD
    Mult Scler; 2013 Oct; 19(12):1640-6. PubMed ID: 23652216
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Estimating a Preference-Based Index for an Eight-Dimensional Health State Classification System for Multiple Sclerosis.
    Goodwin E; Green C; Spencer A
    Value Health; 2015 Dec; 18(8):1025-36. PubMed ID: 26686787
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis.
    Hawton A; Shearer J; Goodwin E; Green C
    Appl Health Econ Health Policy; 2013 Aug; 11(4):331-41. PubMed ID: 23637055
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite.
    Hobart J; Kalkers N; Barkhof F; Uitdehaag B; Polman C; Thompson A
    Mult Scler; 2004 Feb; 10(1):41-6. PubMed ID: 14760951
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A comparison of utility measurement using EQ-5D and SF-6D preference-based generic instruments in patients with rheumatoid arthritis.
    Salaffi F; Carotti M; Ciapetti A; Gasparini S; Grassi W
    Clin Exp Rheumatol; 2011; 29(4):661-71. PubMed ID: 21813061
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A comparison of health utility measures for the evaluation of multiple sclerosis treatments.
    Fisk JD; Brown MG; Sketris IS; Metz LM; Murray TJ; Stadnyk KJ
    J Neurol Neurosurg Psychiatry; 2005 Jan; 76(1):58-63. PubMed ID: 15607996
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost and health related quality of life consequences of multiple sclerosis.
    Grima DT; Torrance GW; Francis G; Rice G; Rosner AJ; Lafortune L
    Mult Scler; 2000 Apr; 6(2):91-8. PubMed ID: 10773854
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Disability weight for each level of the Expanded Disability Status Scale in multiple sclerosis.
    Cho JY; Hong KS; Kim HJ; Kim SH; Min JH; Kim NH; Ahn SW; Park MS; An JY; Kim BJ; Kim W
    Mult Scler; 2014 Aug; 20(9):1217-23. PubMed ID: 24399825
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
    Hawton A; Green C; Telford C; Zajicek J; Wright D
    Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Populating an economic model with health state utility values: moving toward better practice.
    Ara R; Brazier JE
    Value Health; 2010 Aug; 13(5):509-18. PubMed ID: 20230546
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A comparison of physician-rated disease severity and patient reported outcomes in mild to moderately active ulcerative colitis.
    Poole CD; Connolly MP; Nielsen SK; Currie CJ; Marteau P
    J Crohns Colitis; 2010 Sep; 4(3):275-82. PubMed ID: 21122516
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The utility score of epilepsy with partial seizure measured by TTO, VAS, and EQ-5D in the general Korean population.
    Kang HJ; Kang E; Jo MW; Park EJ; Yoon S; Lee EK
    Epilepsy Res; 2014 Jul; 108(5):963-71. PubMed ID: 24679945
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Turkey.
    Karabudak R; Karampampa K; Calışkan Z;
    J Med Econ; 2015 Jan; 18(1):69-75. PubMed ID: 25116693
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries.
    Karampampa K; Gustavsson A; Miltenburger C; Eckert B
    Mult Scler; 2012 Jun; 18(2 Suppl):7-15. PubMed ID: 22623122
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Do Model-Based Studies in Chronic Obstructive Pulmonary Disease Measure Correct Values of Utility? A Meta-Analysis.
    Moayeri F; Hsueh YS; Clarke P; Dunt D
    Value Health; 2016 Jun; 19(4):363-73. PubMed ID: 27325328
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of Personal Resources in Patients Who Differently Estimate the Impact of Multiple Sclerosis.
    Wilski M; Tomczak M
    Ann Behav Med; 2017 Apr; 51(2):179-188. PubMed ID: 27679463
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The relationship between changes in quality of life outcomes and progression of Alzheimer's disease: results from the dependence in AD in England 2 longitudinal study.
    Trigg R; Jones RW; Knapp M; King D; Lacey LA;
    Int J Geriatr Psychiatry; 2015 Apr; 30(4):400-8. PubMed ID: 24920081
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Establishing utility values for the 22-item Sino-Nasal Outcome Test (SNOT-22) using a crosswalk to the EuroQol-five-dimensional questionnaire-three-level version (EQ-5D-3L).
    Crump RT; Lai E; Liu G; Janjua A; Sutherland JM
    Int Forum Allergy Rhinol; 2017 May; 7(5):480-487. PubMed ID: 28182331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.